Live tape
Top 8, mentions 7d10,913GOOGL2,081 mentions▲ +0.04SNDK1,536 mentions▲ +0.11SPCX1,501 mentions▲ +0.08NBIS1,429 mentions▲ +0.10HTZ1,239 mentions▲ +0.10NVDA1,212 mentions▲ +0.08META1,065 mentions▲ +0.03MSFT850 mentions▲ +0.06

Equity · Healthcare

SGRY

Surgery Partners, Inc. · NasdaqGS

$16 −5.88% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 40 sessions
$18 $12 20 May 17 Jul

The line runs $13.50 on 20 May through $16 on 17 July, on a scale from $12 to $18. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of SGRY over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 40 sessions over that window: $13.50 on 20 May 2026 through $16 on 17 July 2026.

Market cap $2.1B
52-week range $11.49 – $23.81
Avg volume 296.5K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026

SGRY insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 18 Jun 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 8

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
18 Jun 2026 HENDRIX BLAIR E Director Award 34,364 $500K
05 Jun 2026 ADLERZ CLIFFORD G Director Award 11,670 $160K
05 Jun 2026 DeLuca Teresa Director Award 11,670 $160K
05 Jun 2026 Dean Lloyd H Director Award 11,670 $160K
05 Jun 2026 Deane John A Director Award 11,670 $160K
05 Jun 2026 Forese Laura L Director Award 11,670 $160K
05 Jun 2026 HENDRIX BLAIR E Director Award 11,670 $160K
05 Jun 2026 TURNER BRENT Director Award 11,670 $160K

SGRY reported financials

SEC EDGAR XBRL

SGRY reported revenue of $3.3B for the fiscal year ended 31 Dec 2025. Net income over the same period was −$77.9M.

Figure Reported Period
Revenue $3.3B 31 Dec 2025 fiscal year
Net income −$77.9M 31 Dec 2025 fiscal year
Diluted EPS −$0.61 31 Dec 2025 fiscal year
Total assets $8.0B 30 Jun 2026 at period end
Total equity $1.7B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

SGRY earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.12 —
31 Mar 2026 Q1 2026 $-0.28 —
31 Dec 2025 FY 2025 $-0.61 —
30 Sep 2025 Q3 2025 $-0.18 —
30 Jun 2025 Q2 2025 $-0.02 —
31 Mar 2025 Q1 2025 $-0.30 —
31 Dec 2024 FY 2024 $-1.33 —
30 Sep 2024 Q3 2024 $-0.25 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

SGRY institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a SGRY position for the quarter ended 30 Jun 2026 — a combined $39.3M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Oaktree Capital Management New position 862,588 $14.5M
Man Group Trimmed −26.3% shares 697,552 $11.7M
Citadel Advisors Trimmed −27.5% shares 291,280 $4.9M
Tudor Investment Corp Trimmed −43.0% shares 153,926 $2.6M
Renaissance Technologies New position 130,100 $2.2M
Marshall Wace Added +643.5% shares 95,362 $1.6M
Balyasny Asset Management New position 64,377 $1.1M
AQR Capital Management Added +286.1% shares 46,155 $775K
Glenview Capital Management Exited
Millennium Management Exited

Source: SEC EDGAR 13F filings

SGRY fails-to-deliver

SEC CNS data

On 31 Jul 2026, 126 shares of SGRY failed to deliver (about $2K).

Settlement date Shares failed Notional % of shares out
31 Jul 2026 126 $2K <0.001%
29 Jul 2026 3,172 $49K 0.002%
28 Jul 2026 487 $7K <0.001%
27 Jul 2026 3,794 $60K 0.003%
24 Jul 2026 1,430 $22K 0.001%
21 Jul 2026 106,602 $1.7M 0.081%
17 Jul 2026 2,692 $45K 0.002%
16 Jul 2026 58 $922 <0.001%
08 Jul 2026 3,031 $52K 0.002%
07 Jul 2026 17,793 $302K 0.014%
06 Jul 2026 2,052 $35K 0.002%

Source: SEC fails-to-deliver (CNS) data